Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab

(2023) Emily S. Lebow et al.   JAMA Network Open

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

(2023) Joao V. Alessi et al.   Journal of Thoracic Oncology

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

(2023) Joao V. Alessi et al.   Nature Communications

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2022) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches

(2022) F. Cortiula et al.   ANNALS OF ONCOLOGY

Tumor aneuploidy predicts survival following immunotherapy across multiple cancers

(2022) Liam F. Spurr et al.   NATURE GENETICS

Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade

(2022) Liam F. Spurr et al.   Nature Cancer

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Quantification of aneuploidy in targeted sequencing data using ASCETS

(2020) Liam F Spurr et al.   BIOINFORMATICS

Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma

(2019) Fumihiko Kinoshita et al.   ANNALS OF SURGICAL ONCOLOGY

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

(2018) Alison M. Taylor et al.   CANCER CELL